EyePoint Pharmaceuticals stock holds at USD 3.25 after loss
EyePoint Pharmaceuticals (EYPT) closed at USD 3.25 on Nasdaq after reporting a significant drop in second-quarter revenue to USD 507,000, down from USD 5.33 million in the prior year. Despite a GAAP net loss of USD 94.47 million, 13 analysts still maintain a "Buy" rating for the stock, with an average 12-month price target of USD 25.91, highlighting the potential upside tied to its late-stage eye-drug pipeline. The company's valuation is heavily influenced by the progress of its investigational sustained-delivery treatment, DURAVYU, for serious retinal diseases.
PV3B Stock Price and Chart — HAN:PV3B
This article provides detailed information on EyePoint, Inc. (PV3B) stock traded on the Hannover Stock Exchange, including key financial stats, upcoming earnings, company info, and analyst insights. It highlights the company's biopharmaceutical focus on eye disorder treatments and includes various trading ideas and forecasts from the TradingView community.
JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
JonesTrading analyst Debanjana Chatterjee has reiterated a Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $20.00. This recommendation comes despite the company reporting a significant GAAP net loss of $94.47 million in its latest quarter, alongside reduced revenue compared to the previous year. Corporate insider sentiment for EYPT is neutral, with a recent sale of shares by the CMO.
EyePoint Pharmaceuticals Inc (PV3B.MU) Analyst Insights, Price Targets & Recommendations - Yahoo Finance
This article provides analyst insights, price targets, and recommendations for EyePoint Pharmaceuticals Inc (PV3B.MU). It details recent upgrades and downgrades from various financial institutions, indicating shifts in analyst sentiment towards the company. The stock closed at 3.1000 EUR, down 3.73%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Pomerantz LLP is investigating potential claims against EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors. This investigation follows a significant stock price drop after EyePoint announced that its pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) did not meet its primary endpoint for treating wet age-related macular degeneration. The firm is examining whether EyePoint and its officers engaged in securities fraud or unlawful business practices.
EyePoint Pharmaceuticals stock holds near its yearly range
EyePoint Pharmaceuticals (EYPT) stock traded near its yearly range on September 23, 2026, with its latest reported period being key for valuation. The company, which develops sustained-delivery medicines for retinal diseases, is a small-cap biotechnology stock where clinical progress, regulatory milestones, and financing needs are central valuation factors. Investors should focus on reported operating figures to assess development risk and the time available to reach clinical milestones rather than daily trading fluctuations.
EyePoint at Morgan Stanley conference: duravyu path stays open By Investing.com
EyePoint Pharmaceuticals (EYPT) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, discussing both challenges and ongoing optimism for its lead wet age-related macular degeneration (wet AMD) program, DURAVYU. Despite missing the primary non-inferiority endpoint in the LUGANO trial, the company highlighted strong secondary results, a clean safety profile, and a potential path to approval if the LUCIA study proves positive. EyePoint also emphasized its diabetic macular edema (DME) program, with data expected in Q4 2027, and stated it has sufficient cash reserves into Q4 2027.
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)
This article highlights bullish sentiments from analysts regarding three healthcare companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT), and Abbott Laboratories (ABT). H.C. Wainwright reiterated a Buy rating for BridgeBio Pharma with a $120.00 price target, while Citi maintained a Buy rating for EyePoint Pharmaceuticals with a $17.00 price target, and also a Buy rating for Abbott Laboratories with a $125.00 price target. The article details analyst consensus ratings and average price targets for each company, indicating potential upsides.
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20
TD Cowen downgraded EyePoint Pharmaceuticals (EYPT) from a Buy rating to Hold and significantly adjusted its price target from $20 to $4. The company currently holds an average overweight rating with a mean price target of $34.55. Access to the full details requires a premium subscription.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
EyePoint (EYPT) recently experienced a sharp fair value reset from US$40.54 to US$25.91, following a split in analyst sentiment due to the LUGANO Phase 3 primary endpoint miss. Despite some bullish takes on positive secondary endpoints and safety data, several firms have downgraded the stock, citing execution risk and regulatory uncertainty for Duravyu. The narrative now focuses on how future trial results, like the LUCIA study, will impact the company's long-term potential and fair value.
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney
Kirby McInerney LLP is investigating potential securities fraud claims against EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant drop in its stock price. This comes after EyePoint announced that its DURAVYU drug missed its primary endpoint in the Phase 3 LUGANO wet AMD trial, contradicting earlier confident statements from the company's CEO. Investors who purchased EyePoint securities are encouraged to contact the law firm to learn more about their rights.
Eyepoint Pharmaceuticals topline Lugano trial results spark momentum for sustained release TKI in wet AMD
Eyepoint Pharmaceuticals announced promising topline results from its Lugano trial for sustained release tyrosine kinase inhibitors (TKIs) in treating wet age-related macular degeneration (AMD). President and CEO Jay S. Duker, M.D., highlighted the potential of long-acting TKI therapies to improve patient outcomes and reduce treatment burden. This announcement follows earlier disclosures regarding the pivotal Phase 3 LUGANO trial of DURAVYU and the company's Q2 2026 financial results, further contextualizing its pipeline development in ophthalmology.
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant drop in its stock price. This decline occurred after the company's DURAVYU drug failed to meet its primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The firm is encouraging investors who suffered losses to submit their information for a potential securities fraud claim.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)
Levi & Korsinsky is investigating potential securities claims against EyePoint Pharmaceuticals (EYPT) after its shares dropped nearly 67% following the failure of its DURAVYU Phase 3 LUGANO trial. The law firm is encouraging shareholders who suffered losses to have their legal rights reviewed, as the company's previous statements about the trial's confidence are under scrutiny. Investors do not incur upfront costs for the review, and eligibility is based on purchase date and documented losses, not current shareholding.
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
Shares of Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) rallied after rival EyePoint Pharmaceuticals (EYPT) reported a setback in its late-stage trial for an eye implant to treat wet age-related macular degeneration. Analysts believe EyePoint's trial failure eases competition for Ocular's similar drug Axpaxli and improves the outlook for 4D Molecular's 4D-150 gene therapy. While EyePoint's stock plummeted, OCUL and FDMT experienced their best trading days in weeks.
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
SueWallSt.com has announced an investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant 67% stock drop after its DURAVYU drug failed to meet its primary endpoint in a Phase 3 trial for wet AMD. The firm is inviting investors who suffered losses to submit their information for a potential securities fraud claim, questioning whether EyePoint made misleading statements about the trial's progress. This investigation highlights concerns about the company's prior assurances regarding the drug's potential before disclosing the trial's failure.
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
EyePoint Pharmaceuticals' stock plummeted 70% after its investigational eye treatment, duravyu, failed its primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wAMD). The drug did not show superiority to aflibercept in improving vision, though EyePoint highlighted positive secondary endpoints and an ad hoc analysis. The company now awaits results from a twin trial, Lucia, as competitor Ocular Therapeutix advances its own wAMD candidate.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold"
Royal Bank of Canada downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from "moderate buy" to "hold," and Cantor Fitzgerald also shifted to a neutral rating. This follows the company's DURAVYU trial missing its primary endpoint, leading to a sharp stock decline and concerns about its future regulatory and commercial success. Despite some analysts maintaining "buy" ratings, the consensus among analysts tracked by MarketBeat is now "Hold" with an average price target of $28.11.
EYPT Stock Crashes On Duravyu Data But Catalysts Loom
EyePoint Pharmaceuticals (EYPT) stock initially crashed by 69% after its Phase 3 LUGANO trial for DURAVYU in wet AMD missed its primary vision endpoint on the full dataset. However, an ad hoc analysis, excluding an asymmetric cohort, showed non-inferiority against aflibercept and other strong secondary outcomes, leading to a rebound. Despite a wider Q2 EPS loss, the company has significant cash reserves and upcoming catalysts, including topline data for the LUCIA trial in Q4 2026 and potential NDA submission in 2027.
Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price
Citigroup has significantly cut its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) from $35.00 to $17.00, while still maintaining a "buy" rating, indicating a potential upside of 216.10% from its current price of $5.38. This downgrade follows the failure of the company's LUGANO trial for DURAVYU to meet its primary endpoint and a reported quarterly loss of $1.09 per share, missing consensus estimates. The stock has seen a sharp decline, trading near its one-year low, and analysts' consensus for EYPT is now a "Hold" with an average target of $28.11.
Eyepoint Pharmaceuticals' (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada
Royal Bank of Canada reiterated its "sector perform" rating for EyePoint Pharmaceuticals (EYPT) but significantly cut its price target to $5 from $37, citing uncertainty after the DURAVYU Phase 3 LUGANO trial missed its primary endpoint. Despite this, other analysts remain divided, with some maintaining "buy" ratings and higher price targets, while the company’s stock price opened at $4.87. The company's Q2 earnings missed analyst estimates, and institutional investors have recently adjusted their holdings in EYPT.
HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy
HC Wainwright has downgraded EyePoint Pharmaceuticals from Buy to Neutral. This follows similar downgrades from other firms like RBC Capital Markets and Chardan, driven by the company's DURAVYU drug failing its primary goal in a Phase 3 wet AMD trial. The downgrades reflect increasing regulatory uncertainty and a significantly reduced average target price for EyePoint.
Jefferies Financial Group Lowers Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $8.00
Jefferies Financial Group has reduced its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) from $30.00 to $8.00, while maintaining a "buy" rating, implying a potential upside of 72.6% from the current price. The stock experienced a significant drop, trading down $10.12 to $4.63, following a quarterly loss that missed analyst estimates. Despite mixed analyst opinions, Eyepoint Pharmaceuticals currently holds a "Moderate Buy" consensus rating with an average price target of $40.33, and institutional investors own a substantial 99.41% of its shares.
The Surprising Reason This Biotech Just Plummeted 67%
EyePoint (EYPT) stock plummeted by 67% after its eye disease treatment, Duravyu, failed to meet its primary goal in a final-phase study for wet age-related macular degeneration. Despite lowering treatment burden and a significant percentage of patients being supplement-free, the drug's inability to achieve its main objective led to a sharp decline in the company's stock value. This unexpected failure highlights the high-risk nature of biotech investments tied to drug trial outcomes.
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
EyePoint, Inc. announced topline data from its LUGANO Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) in wet AMD. While the primary endpoint of change in best corrected visual acuity was not met in the full dataset due to an asymmetric cohort experiencing vision loss unrelated to wet AMD, DURAVYU demonstrated non-inferiority in an ad hoc analysis and showed significant improvements in key secondary endpoints such as treatment burden reduction and high supplement-free rates. EyePoint anticipates filing a New Drug Application in the first half of 2027, pending results from the second Phase 3 trial, LUCIA, expected in Q4 2026.
EyePoint plummets on pivotal data for main drug
EyePoint's main drug, Durayvu, failed to meet its primary goal in a pivotal clinical trial for wet age-related macular degeneration, causing the company's shares to drop significantly. Despite the miss, EyePoint and some analysts believe a path to approval still exists, contingent on the results of a second late-stage trial, LUCIA, expected later this year. The company attributed the trial's failure to an "asymmetric cohort" of patients with vision loss unrelated to wet AMD.
NKE, META, IVF, EYPT, MU: 5 Trending Stocks Today - Micron Technology (NASDAQ:MU)
Major U.S. indices closed lower, but several individual stocks saw significant movement. Nike (NKE) hit a 52-week low due to concerns in the athletic-wear market, and Meta Platforms (META) declined amid legal challenges and AI strategy uncertainties. Conversely, INVO Fertility (IVF) surged after reporting strong Q2 results, while EyePoint (EYPT) plummeted due to mixed Phase 3 clinical trial data. Micron Technology (MU) rose on optimistic analyst projections regarding AI-driven demand and free cash flow potential.
Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today
This article highlights five stocks that captured investor attention on Monday, August 17th, with varied performances. Nike and Meta Platforms experienced declines due to market concerns and legal challenges respectively. In contrast, INVO Fertility saw a significant surge after beating EPS expectations, while EyePoint Pharmaceuticals plummeted due to mixed Phase 3 clinical trial results. Micron Technology rose on optimistic analyst projections driven by AI-fueled demand for memory.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Hits New 12-Month Low Following Analyst Downgrade
Eyepoint Pharmaceuticals (NASDAQ:EYPT) shares dropped to a new 52-week low after Jefferies Financial Group lowered its price target to $8, although maintaining a "buy" rating. This follows the failure of the DURAVYU trial to meet its primary endpoint, raising concerns about the drug's approval despite an adjusted analysis showing non-inferiority to aflibercept. Analyst sentiment is mixed, with a consensus "Moderate Buy" rating, but some firms like Cantor Fitzgerald downgraded the stock to "neutral."
EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden
EyePoint's DURAVYU Phase 3 LUGANO trial for wet age-related macular degeneration missed its primary endpoint in the full dataset. However, secondary data showed a 42% reduction in treatment burden compared to aflibercept, and an ad hoc analysis suggested non-inferiority after excluding certain patients. The focus now shifts to the upcoming LUCIA study results in Q4 2026, which are critical for EyePoint's potential New Drug Application filing in early 2027.
EyePoint Blames Asymmetry For Phase III Trial Failure In Wet AMD
EyePoint Pharmaceuticals reported a failure in its Phase III trial for a wet AMD treatment, attributing it to an "asymmetry" caused by nine patients with pre-existing vision-threatening conditions unrelated to wet AMD. These conditions, including geographic atrophy, glaucoma, and retinal detachment, confounded the primary endpoint results. The company cites these pre-existing issues as the reason for the trial's unsuccessful outcome.
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
EyePoint Pharmaceuticals (EYPT) shares plummeted by 69% after its lead pipeline candidate, Duravyu, missed primary endpoints in two Phase 3 trials for a severe eye disease. Despite management calling the results "clinically meaningful," the market reacted strongly to the trial failure. The article suggests this significant drop might be an overreaction, hinting at potential value in the company post-crash.
Eyepoint Pharmaceuticals stock hits 52-week low at $4.06
Eyepoint Pharmaceuticals (EYPT) stock reached a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with a 58% upside potential, as highlighted by InvestingPro. Recent company news includes stockholder approval for increasing authorized shares and positive analyst coverage from Mizuho and Stifel, raising price targets based on confidence in their retinal disease treatment, Duravyu.
EyePoint's Duravyu misses wet AMD primary endpoint, hinges on second trial for FDA path
EyePoint Pharmaceuticals announced that its drug vorolanib (Duravyu) failed to meet the primary endpoint in the LUGANO Phase III trial for wet age-related macular degeneration (wet AMD), as it did not demonstrate non-inferiority to aflibercept. Despite this setback, the program's FDA path now heavily relies on the results of a second pivotal trial, LUCIA, expected in Q4 2026, due to favorable treatment-burden and safety data from LUGANO. Duravyu aims to offer a six-month dosing interval for wet AMD patients using an office-based, bioerodible intravitreal insert.
EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals announced that its drug DURAVYU failed to meet the primary non-inferiority endpoint in the Phase III LUGANO trial for wet Age-related Macular Degeneration (AMD). The company attributed the miss to nine patients who experienced significant vision loss from conditions unrelated to wet AMD, and an ad hoc analysis excluding these patients did show non-inferiority. Despite this setback, EyePoint remains optimistic about its ongoing LUCIA trial and plans to pursue FDA approval in early 2027 if those results are positive.
EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
EyePoint Pharmaceuticals' stock significantly dropped after its experimental wet age-related macular degeneration (wAMD) treatment, Duravyu, missed its primary goal in a phase 3 trial. The drug-device combo performed worse than Regeneron's Eylea, with an ad hoc analysis suggesting non-wAMD related vision loss in some patients skewed results. Despite this setback, analysts believe a strong performance in the upcoming Lucia trial could still lead to approval for Duravyu.
Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral
Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an "overweight" to a "neutral" rating, causing shares to fall by $10.59 to $4.16, near its 52-week low. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with a target price of $44.38. The company reported a quarterly loss that missed estimates but exceeded revenue expectations.
Eyepoint Pharmaceuticals stock hits 52-week low at $4.06 By Investing.com
Eyepoint Pharmaceuticals Inc. (EYPT) stock recently hit a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with an average price target suggesting a 58% upside. The company recently announced stockholder approval for an increase in authorized shares and the election of new directors, while Mizuho and Stifel have raised price targets based on trial outlook and the potential of its retinal disease treatment, Duravyu.
Form 8K Eyepoint Pharmaceuticals Inc For: 17 August By Investing.com
This article reports on the filing of a Form 8K by Eyepoint Pharmaceuticals Inc. on August 17th. The brief piece includes the stock symbol EYPT, which is noted to be down 68.88%. No further details about the content of the Form 8K are provided.
EYPT Maintains Buy Rating by Chardan Capital -- Price Target Set at $65
Chardan Capital maintained its Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $65.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™ of $0.36 versus its current price of $14.76. The company also received a low GF Score™ of 34/100, indicating significant concerns about financial health, profitability, and growth potential, further complicated by insider selling and mixed guru sentiment. Investors are advised to proceed with caution due to the overvaluation and financial weaknesses.
EYPT Stock Slips As Insider Plans Share Sale
EyePoint Pharmaceuticals (EYPT) stock has dropped significantly following news of an insider's plan to sell securities, as indicated by an amended Form 144/A filing. While the company has a strong balance sheet with substantial cash reserves and a recent multi-week price climb, the insider selling has introduced short-term risk and volatility. Traders are now focusing on price action and risk management due to this shift in sentiment.
EYPT Looks 4000.0% Overvalued on GF Value™
EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but succeeding in secondary outcomes like reducing treatment burden. The company's GF Score™ is low at 34/100 due to weak profitability and growth, but it maintains moderate financial strength and momentum, with investor optimism focused on its pipeline potential.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given "Buy" Rating at Chardan Capital
Chardan Capital has reiterated a "Buy" rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT) with a price target of $65.00, suggesting a significant upside. The company reported a quarterly loss of $1.09 per share, missing estimates, but revenue exceeded expectations. Institutional investors hold a substantial 99.41% stake in the company.
EyePoint’s DURAVYU misses primary endpoint in wet AMD trial
EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority to aflibercept and the drug met several secondary endpoints, including a significant reduction in treatment burden. The company anticipates topline data from its second pivotal trial, LUCIA, in Q4 2026.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced that it granted non-statutory stock options to two new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). These options allow purchase of up to 14,600 shares of common stock with an exercise price of $14.75 per share, vesting over four years. This action is part of the company's commitment to developing therapeutics for serious retinal diseases.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, and vest over four years. This action is part of the company's efforts to attract talent to support its development of therapeutics for serious retinal diseases.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced inducement grants of non-statutory stock options to two new employees for an aggregate of 14,600 shares of common stock. These grants were approved by the Compensation Committee and made in accordance with NASDAQ Listing Rule 5635(c)(4) to induce their employment. The options have an exercise price of $14.75 per share, a ten-year term, and vest over four years.
Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System
The California State Teachers Retirement System significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 2,158.3% in the first quarter, now holding 105,101 shares. Several other institutional investors also adjusted their positions in the company. Despite missing earnings per share estimates, Eyepoint Pharmaceuticals exceeded revenue expectations, and analysts generally maintain a "Moderate Buy" rating with a target price of $44.38.
Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT)
Traders recently purchased a significantly higher volume of Eyepoint Pharmaceuticals (NASDAQ:EYPT) put options, indicating increased bearish sentiment or hedging activity. This comes after the company missed its quarterly EPS expectations, reporting a loss of $1.09 per share against an expected $1.01 loss. Despite the unusual put option activity and weaker earnings, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target significantly above the current trading price.
EyePoint Pharmaceuticals, Inc. (EYPT) options chain
This article provides detailed options chain data for EyePoint Pharmaceuticals, Inc. (EYPT) for the contract date of October 16, 2026. It lists various call and put options, including strike prices, last trade dates, last prices, implied volatility, and other relevant trading metrics. The information reflects the stock's performance at market close and after hours on August 13, 2026.
